Indications

• Prostate Cancer (see Prostate Cancer, [[Prostate Cancer]])

---

Pharmacology

• xxx

---

Administration

• xxxx

Dose Adjustment

• Hepatic:
• Renal:

---

Adverse Effects

Pulmonary Adverse Effects

Interstitial Pneumonits (see Interstitial Lung Disease-Etiology, [[Interstitial Lung Disease-Etiology]])

• Epidemiology: reported in patients treated with combination therapies for prostate cancer
  • Leuprolide + Bicalutamide (see Bicalutamide, [[Bicalutamide]])
  • Leuprolide + Flutamide (see Flutamide, [[Flutamide]])
  • Leuprolide + Nilutamide (see Nilutamide, [[Nilutamide]])

Other Adverse Effects

• xxx
• xxx
• xxx

---

References

• Interstitial pneumonitis associated with neoadjuvant leuprolide and nilutamide for prostate cancer. J Urol. 1998 Jun;159(6):2099 [MEDLINE]
• Interstitial pneumonitis related to leuprorelin acetate and flutamide. J Urol. 1999 Jan;161(1):221 [MEDLINE]
• Interstitial pneumonitis induced by bicalutamide and leuprorelin acetate for prostate cancer. Int J Urol. 2003 Nov;10(11):625-6 [MEDLINE]